Search is Powered by Google
Pharma Industry / Biotech Industry News

Developers Finding Success Of Injectable Drugs Dependent On Numerous Factors -Analysis Trends And Prospects For Six Key Drug Classes

Main Category: Pharma Industry / Biotech Industry
Also Included In: Medical Devices
Article Date: 08 May 2008 - 2:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:not yet rated

Health Professional:not yet rated

Article Opinions: 0 posts

Technology has a way of providing benefits that create complexities, a lesson that drug developers and their supply chain partners are learning to deal with. Historically, the success of new drugs has focused on tolerability, safety, and pharmacokinetics. The challenges of biologically-derived drugs have added new requirements to successful drug development. Because of their far-reaching physiological effects, environmental instability and limited half-lives, recombinant drugs are pushing drug technology in a number of areas including formulation science, packaging, and delivery.

The formulation of biologics is testing the limits of drug development. The use of polymers to stabilize protein and peptide drugs is growing, and advances in drying and reconstitution are providing new options. For drugs designed to be administered by the patient, therapy-specific packaging is improving compliance and treatment outcomes. In the area of delivery, reusable injection devices designed to accept prefilled syringes or drug cartridges is improving ease-of-use and increasing the alternative device share of the growing self-injection market.

In terms of market value, most of the current demand in injectable drugs can be traced to six drug classes. For companies competing in these drug sectors, the stakes are significant and the cost of failure prohibitive. These drugs had total world sales of about $40 billion in 2007. As biological drugs currently in late-stage development become commercialized, the importance of injectable drugs to company business performance will grow considerably.

These findings are contained in a comprehensive report, researched and prepared by Greystone Associates. More information is available at http://www.greystoneassociates.org.

About Greystone

Greystone Associates is a medical and healthcare technology consulting firm providing services in strategic planning, venture development, product commercialization, and technology and market assessment.

Greystone Associates




Weekly Newsletters Daily News Alerts
Home About Us News Licensing Free Website Feeds Free Tools & Content Links Tell a Friend Accessibility Help / FAQ Article Submission Contact Us
Breast Cancer Cardiovascular GI Prostate Cancer Psychiatry Respiratory Learning Resources Migraine Urology
Asthma Bipolar Blood Pressure Breast Cancer (Patient) Heartburn

Sign up to receive newsletters / news alerts
MedReader RSS Reader


Treating Allergic Asthma
Treating Allergic Asthma

Cheryl has suffered from asthma and allergies her whole life. Since her asthma didn't respond well to most treatments, she lived in fear of the next attack. But a new treatment specifically targeting the allergic response that causes her asthma has changed her life.

more videos are available in our health videos section.

Add Your Advertisement Here